Hospital

Targeted therapies, CDK4/6 inhibitors, and precision medicine are improving outcomes for patients with high-risk and metastatic disease.

Rising cancer rates and costs pose challenges in global oncology markets amid AI and targeted therapy breakthroughs.

Experts from Moffitt Cancer Center discuss the benefit of multidisciplinary teams in lung cancer care.

The 2024 NCODA International Fall Summit took place in Orlando, Florida, from October 23 to October 25.

Findings suggest further need to educate the public on receiving an indicated vaccine as we approach peak respiratory syncytial virus (RSV) season.

The INTerpath-009 trial assessed a combination of V940 with pembrolizumab among individuals with stage II, IIIA, IIIB (N2) non–small cell lung cancer.

Stephanie Y. Crawford, PhD, MPH, highlights the expanded roles of pharmacists in clinical and non-clinical settings and their increased role in patient care, sharing personal experiences where pharmacists have been instrumental in supporting her family's health needs.

Though auto-injectors are still considered an appropriate first-line treatment for anaphylaxis, limited evidence exists surrounding their effectiveness in preventing fatal anaphylaxis.

The approval marks the first and only abuse-deterrent immediate release oxycodone formulation.

Apalutamide is a hormone therapy indicated for men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Islatravir in combination with lenacapavir could become the first weekly oral HIV treatment.

Investigators found that electronic letter reminders were most effective for older individuals, those who were unvaccinated in the preceding season, those with cardiovascular disease, and those with diabetes.

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

Zaltenibart could be an effective treatment option for C3 glomerulopathy as the most proximal inhibitor of the alternative pathway.

NCCN recommends ribociclib as a preferred CDK4/6 inhibitor adjuvant therapy for patients with HR+/HER2- EBC in combination with an aromatase inhibitor.

Utilizing data from the CHAMPION MG trial, investigators found that many patients had responded to ravulizumab and returned to daily activities within 2 weeks.

Historically, colchicine has been used primarily in the management of gout; however, in 2023, the FDA approved Lodoco, a newly marketed colchicine product, for the management of cardiovascular disease.

Congenital muscular dystrophy type 1a is a severe, early-onset condition that currently has no treatment, but MDL-101 may serve as a 1-time, durable treatment option.

Sara Rogers, PharmD, discusses the formation and goals of the Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) initiative, which seeks to standardize pharmacogenomic practices and improve clinical decision-making by establishing consensus across all stakeholders.

Findings highlight the need for health care providers to continue to educate patients on the risk of scurvy, ensuring proper vitamin C intake.

Pharmacists are encouraged to leverage prescription drug monitoring programs connect patients to community-based resources to address the opioid crisis and pharmacy deserts.

Ryan Nelson, PharmD, discusses the STRIPE Annual Meeting and Consensus Workshop’s focus on unifying pharmacogenetic guidelines across major organizations, such as the FDA, European Medicines Agency, Clinical Pharmacogenetics Implementation Consortium, and National Comprehensive Cancer Network.

Damage to a Baxter manufacturing plant in the aftermath of Hurricane Helene has led to significant IV fluid shortages throughout the country.

Treatment with valacyclovir for a year decreased the risk of new or worsening eye disease by 26%.

Despite self-reported improvements in cognitive function, neuropsychological tests showed little differences between 2 patient groups.

Benjamin Brown of Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) discusses his own experience as a patient with cancer and how consensus around pharmacogenomic practices can improve the lives of patients.

The approval marks Abrysvo as the first and only RSV vaccine designated for adults younger than 50 that are at increased risk for LRTD.

Benefits include reducing serious health consequences, such as hospitalization and death, as well as the economic burden on health systems due to influenza infection.

Higher doses of β-blockers are associated with better clinical outcomes in patient with heart failure.

Pharmacists will likely be the first contact for many affected patients, and they should be able to provide evidence-based advice on how to manage their infection.